Forest's Saunders ropes 2nd major sale, boosts personal brand in Actavis deal
This article was originally published in Scrip
Executive Summary
Forest Laboratories president and CEO Brent Saunders has positioned himself as a most-wanted man in the biopharma industry with his second multibillion-dollar sale of a specialty pharmaceutical company in less than a year.
You may also be interested in...
Bausch + Lomb Turns To Familiar Face As CEO, Brent Saunders
Saunders will oversee the consumer health, pharma and medtech eye health and vision care specialist, returning to where he got his start as a chief executive before earning a reputation as one of industry’s biggest dealmakers.
Bausch + Lomb Taps A Familiar Face, Brent Saunders, As Next CEO
Saunders will oversee the eye specialist, returning to the firm where he got his start as a chief executive before earning a reputation as one of industry’s biggest dealmakers.
Full Circle: Allergan's Revenue Growth Fuels Reinvestment In Sales, R&D
Allergan generated enough cash flow in the first quarter to justify increased spending to develop and promote new products in 2017 – reinvesting because it can, not necessarily because it has to.